These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9129773)

  • 41. Safety of insulin pumps, even in adolescent use, depends on thorough patient selection, evaluation, and education.
    Exelbert LL
    Pediatrics; 2008 Sep; 122(3):682; author reply 682-3. PubMed ID: 18762546
    [No Abstract]   [Full Text] [Related]  

  • 42. [Insulin doses adaptation with insulin Lys-pro in external pump].
    Grimaldi A; Sachon C; Timsit J
    Diabetes Metab; 2001 Jun; 27(3):386-7. PubMed ID: 11431606
    [No Abstract]   [Full Text] [Related]  

  • 43. 2009 resource guide. Insulin (and other injected drugs).
    Diabetes Forecast; 2009 Jan; 62(1):41-6. PubMed ID: 19445085
    [No Abstract]   [Full Text] [Related]  

  • 44. Catheter complications associated with implantable systems for peritoneal insulin delivery. An analysis of frequency, predisposing factors, and obstructing materials.
    Renard E; Baldet P; Picot MC; Jacques-Apostol D; Lauton D; Costalat G; Bringer J; Jaffiol C
    Diabetes Care; 1995 Mar; 18(3):300-6. PubMed ID: 7555471
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multicentre trial of a programmable implantable insulin pump in type I diabetes. The Point Study II Group.
    Int J Artif Organs; 1995 Jun; 18(6):322-5. PubMed ID: 8593967
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High antigenicity of intraperitoneal insulin infusion via implantable devices: preliminary rat studies.
    Jeandidier N; Boullu S; Delatte E; Sapin R; Steibel J; Meyer P; Uhl C; Pinget M
    Horm Metab Res; 2001 Jan; 33(1):34-8. PubMed ID: 11280713
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity of long-term intraperitoneal insulin administration with implantable programmable pumps. Metabolic consequences.
    Lassmann-Vague V; Belicar P; Raccah D; Vialettes B; Sodoyez JC; Vague P
    Diabetes Care; 1995 Apr; 18(4):498-503. PubMed ID: 7497859
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [In vivo evaluation of the new antithrombogenic reservoir-catheter coated with polymer blend copolymer].
    Matsumoto S; Yamada Y; Kiyosue H; Dono S; Mori H; Imagawa M; Nomura Y; Toyoda H; Shimada T
    Nihon Igaku Hoshasen Gakkai Zasshi; 1997 Apr; 57(5):238-43. PubMed ID: 9164111
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Delivering insulin 'round the clock.
    Fain JA
    Nursing; 2002 Aug; 32(8):54-6. PubMed ID: 12352854
    [No Abstract]   [Full Text] [Related]  

  • 50. Scintigraphic monitoring of catheter-port systems in type I diabetics with continuous insulin therapy.
    Lindner O; Klein E; Franzke K; Petzoldt R; Burchert W
    Exp Clin Endocrinol Diabetes; 2004 Mar; 112(3):148-52. PubMed ID: 15052535
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Port visualization before intraperitoneal chemotherapy: scintigraphy or angiography?].
    Brecht-Krauss D; Vogel J; Hepp G
    Rofo; 1991 Jun; 154(6):638-42. PubMed ID: 1648768
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnostic procedures for catheter malfunction in programmable implantable intraperitoneal insulin infusion devices.
    Olsen CL; Turner DS; Iravani M; Waxman K; Selam JL; Charles MA
    Diabetes Care; 1995 Jan; 18(1):70-6. PubMed ID: 7698051
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Macrophage activation in type 1 diabetic patients with catheter obstruction during peritoneal insulin delivery with an implantable pump.
    Kessler L; Tritschler S; Bohbot A; Sigrist S; Karsten V; Boivin S; Dufour P; Belcourt A; Pinget M
    Diabetes Care; 2001 Feb; 24(2):302-7. PubMed ID: 11213883
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Experience of long-term intraperitoneal insulin treatment using a new percutaneous access device.
    Wredling R; Adamson U; Lins PE; Backman L; Lundgren D
    Diabet Med; 1991 Jul; 8(6):597-600. PubMed ID: 1832367
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An open-loop insulin delivery device for the control of experimental diabetes.
    Albisser AM; Jackman WS; Ferguson R; Bahoric A; Goriya Y
    Horm Metab Res Suppl; 1979; (8):51-7. PubMed ID: 395090
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Implantable insulin pump therapy: an unusual presentation of a catheter-related complication.
    Moore KB; Saudek CD; Greene A; Dackiw A
    Diabetes Technol Ther; 2006 Jun; 8(3):397-401. PubMed ID: 16800761
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Subcutaneous insulin pumps].
    Bourgon C
    Soins; 1991 May; (548):29-30, 32-4. PubMed ID: 1853235
    [No Abstract]   [Full Text] [Related]  

  • 58. Insulin underdelivery from implanted pumps using peritoneal route. Determinant role of insulin pump compatibility.
    Renard E; Bouteleau S; Jacques-Apostol D; Lauton D; Gibert-Boulet F; Costalat G; Bringer J; Jaffiol C
    Diabetes Care; 1996 Aug; 19(8):812-7. PubMed ID: 8842596
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A portable precision pumping system for chronic, programmed insulin infusion.
    Albisser AM; Jackman WS; Ferguson R; Bahoric A; Goriya Y
    Med Prog Technol; 1978 May; 5(4):187-93. PubMed ID: 672822
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intraperitoneal insulin therapy in patients with type 1 diabetes. Does it fit into the current therapeutic arsenal?
    Giménez M; Purkayajtha S; Moscardó V; Conget I; Oliver N
    Endocrinol Diabetes Nutr (Engl Ed); 2018 Mar; 65(3):182-184. PubMed ID: 29429951
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.